Alkermes Plc. ALKS
We take great care to ensure that the data presented and summarized in this overview for Alkermes plc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALKS
View all-
Black Rock Inc. New York, NY29.1MShares$844 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$528 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$342 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$232 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$200 Million3.72% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny5.74MShares$166 Million0.3% of portfolio
-
Jpmorgan Chase & CO New York, NY5.23MShares$152 Million0.01% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.79MShares$139 Million0.18% of portfolio
-
Baker Bros. Advisors LP New York, NY4.48MShares$130 Million1.76% of portfolio
-
Geode Capital Management, LLC Boston, MA3.94MShares$114 Million0.01% of portfolio
Latest Institutional Activity in ALKS
Top Purchases
Top Sells
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Transactions at ALKS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 10
2025
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,334
-3.72%
|
$103,354
$31.09 P/Share
|
Jun 09
2025
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,333
-3.59%
|
$103,323
$31.95 P/Share
|
Jun 08
2025
|
Christopher I Wright Director |
SELL
Payment of exercise price or tax liability
|
Direct |
793
-3.33%
|
$24,583
$31.71 P/Share
|
Jun 08
2025
|
Christopher I Wright Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,301
+12.18%
|
-
|
May 31
2025
|
Cato T Laurencin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-6.2%
|
$57,720
$30.61 P/Share
|
May 31
2025
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,013
+20.53%
|
-
|
May 31
2025
|
Nancy Lurker Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-15.23%
|
$57,720
$30.61 P/Share
|
May 31
2025
|
Nancy Lurker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,013
+38.82%
|
-
|
May 31
2025
|
Brian P Mckeon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-5.38%
|
$57,720
$30.61 P/Share
|
May 31
2025
|
Brian P Mckeon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,013
+18.29%
|
-
|
May 31
2025
|
Nancy Lynn Md Snyderman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-15.21%
|
$57,720
$30.61 P/Share
|
May 31
2025
|
Nancy Lynn Md Snyderman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,013
+38.78%
|
-
|
May 31
2025
|
Frank Anders Wilson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-5.83%
|
$57,720
$30.61 P/Share
|
May 31
2025
|
Frank Anders Wilson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,013
+19.53%
|
-
|
May 31
2025
|
Christopher I Wright Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-8.58%
|
$57,720
$30.61 P/Share
|
May 31
2025
|
Christopher I Wright Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,013
+26.32%
|
-
|
May 31
2025
|
Shane Cooke Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,175
-3.87%
|
$125,250
$30.61 P/Share
|
May 31
2025
|
Shane Cooke Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,013
+6.91%
|
-
|
May 31
2025
|
Richard Gaynor Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-5.83%
|
$57,720
$30.61 P/Share
|
May 31
2025
|
Richard Gaynor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,013
+19.53%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 776K shares |
---|---|
Grant, award, or other acquisition | 341K shares |
Payment of exercise price or tax liability | 220K shares |
---|---|
Open market or private sale | 626K shares |